Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Manfred Volm

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Physiology

Chemicals & Drugs

Procedures

Living Beings

Anatomy

Cultured Tumor Cells

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
89
Mattern, Jürgen
45
Koomägi, Reet
23
Stammler, Gerd
20
Sauerbrey, Axel
13
Zintl, Felix
9
Efferth, Thomas
8
Koomagi, R
5
Rittgen, Werner
4
Hahn, Eric
2
Wallwiener, Diethelm
1
Weber, Oliver
1
Weirich, Angela
1
Wolber, Gerd
1
Zerban, Heide
1
Halatsch, Marc-Eric

Sign-in to see all Coauthors

Publications

TOP 3
Efferth Thomas; Konkimalla V Badireenath; Wang Yi-Fen; Sauerbrey Axel; Meinhardt Silke; Zintl Felix; Mattern Jürgen; Volm Manfred
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Lippert Theodor H; Ruoff Hans-Jörg; Volm Manfred
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Lippert Theodor Hermann; Ruoff Hans-Jörg; Volm Manfred
Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Manfred Volm (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Efferth Thomas; Konkimalla V Badireenath; Wang Yi-Fen; Sauerbrey Axel; Meinhardt Silke; Zintl Felix; Mattern Jürgen; Volm Manfred
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2405-12.
2008: Lippert Theodor H; Ruoff Hans-Jörg; Volm Manfred
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Arzneimittel-Forschung 2008;58(6):261-4.
2008: Lippert Theodor Hermann; Ruoff Hans-Jörg; Volm Manfred
Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?
Pharmacology 2008;81(3):196-203.
2005: Efferth Thomas; Volm Manfred
Pharmacogenetics for individualized cancer chemotherapy.
Pharmacology & therapeutics 2005;107(2):155-76.
2005: Efferth Thomas; Volm Manfred
Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
In vivo (Athens, Greece) 2005;19(1):225-32.
2004: Mattern Jürgen; Volm Manfred
Imbalance of cell proliferation and apoptosis during progression of lung carcinomas.
Anticancer research 2004;24(6):4243-6.
2003: Efferth Thomas; Sauerbrey Axel; Olbrich Armin; Gebhart Erich; Rauch Pia; Weber H Oliver; Hengstler Jan G; Halatsch Marc-Eric; Volm Manfred; Tew Kenneth D; Ross Douglas D; Funk Jens Oliver
Molecular modes of action of artesunate in tumor cell lines.
Molecular pharmacology 2003;64(2):382-94.
2003: Volm Manfred; Koomägi Reet
Prognostic relevance of angiogenic, proliferative, and apoptotic factors in lung carcinomas. A case review.
Methods in molecular medicine 2003;74():269-82.
2003: Volm Manfred; Koomägi Reet; Rittgen Werner
Cellular predictive factors of drug resistance in non-small cell lung carcinomas.
Methods in molecular medicine 2003;75():39-51.
2002: Mattern Jürgen; Koomägi Reet; Volm Manfred
Expression of drug resistance gene products during progression of lung carcinomas.
Oncology reports 2002;9(6):1181-4.
2002: Volm M; Sauerbrey A; Zintl F; Koomägi R; Efferth T
Protein expression profile of newly diagnosed acute lymphoblastic leukemia in children developing relapses.
Oncology reports 2002;9(5):965-9.
2002: Volm M; Koomägi R; Mattern J; Efferth T
Protein expression profiles indicative for drug resistance of non-small cell lung cancer.
British journal of cancer 2002;87(3):251-7.
2002: Volm Manfred; Koomägi Reet; Efferth Thomas; Mattern Jürgen
Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype.
Anticancer research 2002;22(4):2321-4.
2002: Volm Manfred; Koomägi Reet; Mattern Jürgen; Efferth Thomas
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1843-8.
2002: Mattern Jürgen; Koomägi Reet; Volm Manfred
Characteristics of long-term survivors of untreated lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;36(3):277-82.
2002: Efferth Thomas; Koomägi Reet; Mattern Jürgen; Volm Manfred
Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice.
International journal of oncology 2002;20(2):391-5.
2002: Masanek Ulrike; Stammler Gerd; Volm Manfred
Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides.
Journal of experimental therapeutics & oncology 2002;2(1):37-41.
2002: Volm Manfred; Koomägi Reet; Mattern Jürgen; Efferth Thomas
Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.
Clinical & experimental metastasis 2002;19(5):385-90.
2001: Mattern J; Volm M
Clinical estimation of the growth rate of lung cancer.
Anticancer research 2001;21(6A):4067-70.
2001: Koomagi R; Zintl F; Sauerbrey A; Volm M
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3381-4.
2000: Volm M; Rittgen W
Cellular predictive factors for the drug response of lung cancer.
Anticancer research 2000;20(5B):3449-58.
2000: Volm M; Mattern J; Koomägi R
Angiostatin expression in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(8):3236-40.
2000: Volm M; Koomägi R
Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer.
Anticancer research 2000;20(3A):1527-33.
2000: Volm M; Koomägi R
Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
British journal of cancer 2000;82(10):1747-54.
2000: Koomägi R; Volm M
Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer.
Anticancer research 2000;20(1B):493-6.
2000: Volm M; Koomagi R
Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer.
Oncology reports 2000;7(1):95-8.
2000: Volm M; Mattern J; Koomägi R
Association of telomerase expression with successful heterotransplantation of lung cancer.
International journal of oncology 2000;16(1):31-5.
1999: Koomägi R; Mattern J; Volm M
Glucose-related protein (GRP78) and its relationship to the drug-resistance proteins P170, GST-pi, LRP56 and angiogenesis in non-small cell lung carcinomas.
Anticancer research 1999;19(5B):4333-6.
1999: Volm M; Zintl F; Sauerbrey A; Koomägi R
Proliferation and apoptosis in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.
Anticancer research 1999;19(5B):4327-31.
1999: Volm M; Zintl F; Sauerbrey A; Koomägi R
Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.
Anticancer research 1999;19(4C):3399-402.
1999: Volm M; Koomägi R
Association of cyclin D1 expression in lung cancer and the smoking habits of patients.
Cancer letters 1999;141(1-2):147-50.
1999: Mattern J; Koomägi R; Volm M
Biological characterization of subgroups of squamous cell lung carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1459-63.
1999: Koomägi R; Volm M
Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance.
International journal of cancer. Journal international du cancer 1999;84(3):239-43.
1999: Mattern J; Koomägi R; Volm M
Xenotransplantability of human squamous cell lung cancer in nude mice is not affected by angiogenic factors.
Anticancer research 1999;19(3A):1941-3.
1999: Volm M; Mattern J; Koomägi R
Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.
Anticancer research 1999;19(3A):1669-71.
1999: Volm M; Mattern J; Koomagi R
Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival.
Oncology reports 1999;6(3):611-5.
1999: Volm M; Koomagi R
The implications of proliferation and apoptosis for lung cancer metastasis.
Oncology reports 1999;6(2):373-6.
1999: Volm M; Koomägi R; Mattern J
Angiogenesis and cigarette smoking in squamous cell lung carcinomas: an immunohistochemical study of 28 cases.
Anticancer research 1999;19(1A):333-6.
1999: Volm M; Koomägi R; Mattern J
PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis.
Anticancer research 1999;19(1B):651-5.
1998: Koomägi R; Sauerbrey A; Zintl F; Volm M
nm23-H1 protein expression in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.
Anticancer research 1998;18(6A):4307-9.
1998: Mattern J; Koomägi R; Volm M
Xenotransplantability of human cancers in mice.
Journal of the National Cancer Institute 1998;90(22):1747-9.
1998: Volm M; Mattern J; Koomagi R
Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors.
International journal of oncology 1998;13(5):975-9.
1998: Volm M; Mattern J; Koomägi R
Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas.
Clinical & experimental metastasis 1998;16(7):595-602.
1998: Mattern J; Eichhorn U; Kaina B; Volm M
O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.
International journal of cancer. Journal international du cancer 1998;77(6):919-22.
1998: Volm M
Multidrug resistance and its reversal.
Anticancer research 1998;18(4C):2905-17.
1998: Volm M; Koomägi R; Mattern J
Prognostic value of p16INK4A expression in lung adenocarcinoma.
Anticancer research 1998;18(4A):2309-12.
1998: Mattern J; Koomägi R; Volm M
Smoking-related increase of O6-methylguanine-DNA methyltransferase expression in human lung carcinomas.
Carcinogenesis 1998;19(7):1247-50.
1998: Volm M; Koomägi R; Rittgen W
Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma.
International journal of cancer. Journal international du cancer 1998;79(3):294-9.
1998: Koomägi R; Volm M
Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis.
International journal of cancer. Journal international du cancer 1998;79(1):19-22.
1998: Volm M; Rittgen W; Drings P
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
British journal of cancer 1998;77(4):663-9.
1998: Mattern J; Stammler G; Koomagi R; Wallwiener D; Kaufmann M; Volm M
Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor.
International journal of oncology 1998;12(2):351-4.
1997: Volm M; Mattern J; Koomägi R
Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance.
Anti-cancer drugs 1997;8(10):931-6.
1997: Volm M; Koomägi R; Stammler G; Rittgen W; Zintl F; Sauerbrey A
Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia.
International journal of cancer. Journal international du cancer 1997;74(5):508-12.
1997: Volm M; Stammler G; Zintl F; Koomägi R; Sauerbrey A
Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia.
Anti-cancer drugs 1997;8(7):662-5.
1997: Stammler G; Zintl F; Sauerbrey A; Volm M
Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.
Anti-cancer drugs 1997;8(5):517-21.
1997: Mattern J; Koomägi R; Volm M
Coexpression of VEGF and bFGF in human epidermoid lung carcinoma is associated with increased vessel density.
Anticancer research 1997;17(3C):2249-52.
1997: Volm M; Koomägi R; Mattern J; Stammler G
Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas.
European journal of cancer (Oxford, England : 1990) 1997;33(4):691-3.
1997: Stammler G; Volm M
Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines.
Anti-cancer drugs 1997;8(3):265-8.
1997: Masanek U; Stammler G; Volm M
Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.
Anti-cancer drugs 1997;8(2):189-98.
1997: Volm M; Koomägi R; Mattern J
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer.
International journal of cancer. Journal international du cancer 1997;74(1):64-8.
1997: Volm M; Zintl F; Edler L; Sauerbrey A
Prognostic value of protein kinase C, proto-oncogene products and resistance-related proteins in newly diagnosed childhood acute lymphoblastic leukemia.
Medical and pediatric oncology 1997;28(2):117-26.
1997: Volm M; Koomägi R; Mattern J; Stammler G
Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.
Anticancer research 1997;17(1A):99-103.
1997: Mattern J; Stammler G; Koomagi R; Wallwiener D; Kaufmann M; Volm M
Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.
Anticancer research 1997;17(1B):621-4.
1997: Stammler G; Sauerbrey A; Zintl F; Volm M
Apoptotic index, Fas and bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia.
Apoptosis : an international journal on programmed cell death 1997;2(4):377-83.
1997: Volm M; Koomägi R; Mattern J; Stammler G
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
British journal of cancer 1997;75(12):1774-8.
1996: Koomägi R; Stammler G; Manegold C; Mattern J; Volm M
Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer.
Cancer letters 1996;110(1-2):129-36.
1996: Mattern J; Kallinowski F; Herfarth C; Volm M
Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer.
International journal of cancer. Journal international du cancer 1996;67(1):20-3.
1996: Volm M; Koomagi R; Kaufmann M; Mattern J; Stammler G
Microvessel density, expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas.
Clinical & experimental metastasis 1996;14(3):209-14.
1996: Mattern J; Koomägi R; Volm M
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
British journal of cancer 1996;73(7):931-4.
1996: Volm M; Stammler G
Retinoblastoma (Rb) protein expression and resistance in squamous cell lung carcinomas.
Anticancer research 1996;16(2):891-4.
1996: Volm M; Koomägi R; van Kaick G; Mattern J
[Vascular thickness and cytostatic-resistant bronchial carcinoma]
Deutsche medizinische Wochenschrift (1946) 1996;121(10):291-4.
1996: Stammler G; Pommerenke E W; Masanek U; Mattern J; Volm M
Messenger RNA expression of resistance factors in human tumor cell lines after single exposure to radiation.
Journal of experimental therapeutics & oncology 1996;1(1):39-48.
1996: Volm M; Koomägi R; Mattern J
Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma.
Anticancer research 1996;16(1):213-7.
1996: Stammler G; Volm M
Expression of heat shock proteins, glutathione peroxidase and catalase in childhood acute lymphoblastic leukemia and nephroblastoma.
Cancer letters 1996;99(1):35-42.
1996: Volm M; Mattern J
Resistance mechanisms and their regulation in lung cancer.
Critical reviews in oncogenesis 1996;7(3-4):227-44.
1995: Volm M; Mattern J; Stammler G
Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers.
Anticancer research 1995;15(6B):2607-9.
1995: Volm M; Mattern J; Stammler G; Royer-Pokora B; Schneider S; Weirich A; Ludwig R
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
International journal of cancer. Journal international du cancer 1995;63(2):193-7.
1995: Stammler G; Pommerenke E W; Mattern J; Volm M
Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells.
Carcinogenesis 1995;16(9):2051-5.
1995: Volm M; Koomägi R; Mattern J; Stammler G
Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas.
Cancer letters 1995;95(1-2):195-200.
1995: Volm M; Hecker S; Sauerbrey A; Mattern J
Predictive value of statin, a G0-associated cell cycle protein, in childhood acute lymphoblastic leukemia.
International journal of cancer. Journal international du cancer 1995;64(3):166-70.
1995: Mattern J; Sauerbrey A; Volm M
p53 protein detected by two different antibodies: relationship to proliferation and prognosis in acute lymphoblastic leukemia.
Anticancer research 1995;15(3):1043-7.
1995: Volm M; Pommerenke E W
Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer.
Anticancer research 1995;15(2):463-6.
1995: Pommerenke E W; Volm M
Reversal of doxorubicin-resistance in solid tumors by clomipramine.
In vivo (Athens, Greece) 1995;9(2):99-101.
1995: Stammler G; Sauerbrey A; Volm M
Messenger RNA expression of resistance factors and their correlation to the proliferative activity in childhood acute lymphoblastic leukemia.
Cancer letters 1995;89(1):129-35.
1994: Hecker S; Sauerbrey A; Volm M
p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.
Anticancer research 1994;14(6B):2759-61.
1994: Sauerbrey A; Zintl F; Volm M
Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia.
Annals of hematology 1994;69(3):111-5.
1994: Stammler G; Sauerbrey A; Volm M
Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR.
Cancer letters 1994;84(2):141-7.
1994: Volm M; van Kaick G; Mattern J
Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases.
Clinical & experimental metastasis 1994;12(4):329-34.
1994: Volm M; Sauerbrey A; Zintl F
Dihydrofolate-reductase and thymidylate-synthase in childhood acute lymphoblastic leukemia.
Anticancer research 1994;14(3B):1377-81.
1994: Volm M; Zintl F; Sauerbrey A
Thymidylate synthase in childhood acute non-lymphoblastic leukemia.
Anticancer research 1994;14(3B):1271-5.
1994: Mattern J; Volm M
Detection of resistance proteins in matched primary lung tumors and lymph node metastases.
Anticancer research 1994;14(2A):417-9.
1994: Volm M; Efferth T
[Overcoming resistance in tumors]
Deutsche medizinische Wochenschrift (1946) 1994;119(13):475-9.
1994: Pommerenke E; Mattern J; Volm M
Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.
Journal of cancer research and clinical oncology 1994;120(7):422-6.
1993: Volm M; Mattern J
Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Anticancer research 1993;13(6A):2021-5.
1993: Efferth T; Volm M
Increase of alkaline phosphatase in multidrug-resistant tumor cells and their cross-resistance to 6-thioguanine.
Arzneimittel-Forschung 1993;43(10):1118-21.
1993: Efferth T; Volm M
Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms.
Cancer letters 1993;70(3):197-202.
1993: Efferth T; Dunn T A; Berlion M; Langenbahn H; Pommerenke E W; Volm M
Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.
Anticancer research 1993;13(4):905-8.
1993: Volm M; Drings P; Wodrich W; van Kaick G
Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases.
Clinical & experimental metastasis 1993;11(4):325-9.
1993: Efferth T; Volm M
Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells.
Oncology 1993;50(4):303-8.
1993: Wodrich W; Volm M
Overexpression of oncoproteins in non-small cell lung carcinomas of smokers.
Carcinogenesis 1993;14(6):1121-4.
1993: Volm M; Kästel M; Mattern J; Efferth T
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Cancer 1993;71(12):3981-7.
1993: Volm M
P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas.
Anticancer research 1993;13(2):375-8.
1993: Volm M; Drings P; Wodrich W
Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas.
Journal of cancer research and clinical oncology 1993;119(9):507-10.
1992: Efferth T; Volm M
Expression of protein kinase C in human renal cell carcinoma cells with inherent resistance to doxorubicin.
Anticancer research 1992;12(6B):2209-11.
1992: Volm M; Mattern J
Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.
Anticancer research 1992;12(6B):2293-6.
1992: Volm M; Mattern J
Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habits.
Carcinogenesis 1992;13(11):1947-50.
1992: Mattern J; Volm M
[The individualized therapy of tumors]
Deutsche medizinische Wochenschrift (1946) 1992;117(44):1685-9.
1992: Volm M; Efferth T; Mattern J; Pommerenke E W
Resistance mechanisms in murine tumors with acquired multidrug resistance.
Arzneimittel-Forschung 1992;42(9):1163-8.
1992: Volm M; Mattern J; Samsel B
Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors.
Cancer 1992;70(4):764-9.
1992: Volm M; Mattern J; Efferth T; Pommerenke E W
Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
Anticancer research 1992;12(4):1063-7.
1992: Mattern J; Volm M
Prediction of drug resistance in human tumors using immunohistochemical techniques.
Anticancer research 1992;12(2):413-8.
1992: Volm M; Efferth T; Mattern J
Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations.
Anticancer research 1992;12(1):11-20.
1992: Efferth T; Volm M
Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance.
Cancer detection and prevention 1992;16(4):237-43.
1992: Efferth T; Mattern J; Volm M
Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors.
Oncology 1992;49(5):368-75.
1991: Volm M; Mattern J; Samsel B
Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.
British journal of cancer 1991;64(4):700-4.
1991: Pommerenke E W; Mattern J; Traugott U; Volm M
[Reversal of multidrug resistance with (R)-verapamil in vitro and in vivo]
Arzneimittel-Forschung 1991;41(8):855-8.
1991: Volm M; Mattern J; Samsel B
[The prevalence of cytostatic-resistant lung tumors in smokers]
Deutsche medizinische Wochenschrift (1946) 1991;116(35):1303-6.
1991: Efferth T; Lathan B; Volm M
Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4.
British journal of cancer 1991;64(1):87-9.
1991: Efferth T; Klett T; Mattern J; Osswald H; Pommerenke E W; Stöhr M; Volm M
Reversing multidrug resistance in L1210 tumor cells by hycanthone or chlorophenoxamine in vitro and in vivo.
Anticancer research 1991;11(3):1275-9.
1991: Volm M; Pommerenke E W; Efferth T; Löhrke H; Mattern J
Circumvention of multi-drug resistance in human kidney and kidney carcinoma in vitro.
Cancer 1991;67(10):2484-9.
1991: Volm M; Mattern J; Pommerenke E W
Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
Anticancer research 1991;11(2):579-85.
1990: Pommerenke E W; Osswald H; Hahn E W; Volm M
Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells.
Cancer letters 1990;55(1):17-23.
1990: Volm M; Samsel B; Mattern J
Relationship between chemoresistance of lung tumours and cigarette smoking.
British journal of cancer 1990;62(2):255-6.
1990: Mattern J; Bak M; Volm M
Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.
Anticancer research 1990;10(1):177-80.
1990: Volm M; Zerban H; Mattern J; Efferth T
Overexpression of P-glycoprotein in rat hepatocellular carcinomas induced with N-nitrosomorpholine.
Carcinogenesis 1990;11(1):169-72.
1990: Schneider J; Edler L; Kleine W; Volm M
DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma.
Archives of gynecology and obstetrics 1990;248(1):45-52.
1990: Efferth T; Löhrke H; Volm M
Correlations between natural resistance to doxorubicin, proliferative activity, and expression of P-glycoprotein 170 in human kidney tumor cell lines.
Urological research 1990;18(5):309-12.
1990: Volm M; Efferth T
Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests.
Cytometry 1990;11(3):406-10.
1989: Mattern J; Bak M; Hoever K H; Volm M
Radiosensitivity of drug-resistant human tumour xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(12):870-2.
1989: Schneider J; Bak M; Efferth T; Kaufmann M; Mattern J; Volm M
P-glycoprotein expression in treated and untreated human breast cancer.
British journal of cancer 1989;60(6):815-8.
1989: Mattern J; Volm M
[P glycoprotein as a resistance marker in tumors]
Deutsche medizinische Wochenschrift (1946) 1989;114(50):1979-81.
1989: Efferth T; Löhrke H; Volm M
Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors.
Anticancer research 1989;9(6):1633-7.
1989: Volm M; Kleine W; Pfleiderer A
Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: a 5-year follow-up study.
Gynecologic oncology 1989;35(1):84-9.
1989: Volm M; Efferth T; Mattern J
Acquired drug resistance in human lung carcinoma xenografts.
Arzneimittel-Forschung 1989;39(8):828-31.
1989: Volm M; Kayser K; Mattern J
[Demonstration of independent cellular prognostic factors in squamous cell carcinoma of the lung]
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(8):587-92.
1989: Mattern J; Edler L; Volm M
Quantitative analysis of resistance and cross-resistance to cytotoxic agents by tumour cell lines.
Anticancer research 1989;9(4):833-6.
1989: Volm M; Bak M; Mattern J
Intrinsic multidrug resistance in human lung carcinomas grown in nude mice.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):524-6.
1989: Bak M; Mattern J; Volm M
Comparative histopathology of human epidermoid lung carcinoma xenografts.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(7):485-6.
1989: Hahn E W; Wolber G; Bak M; Hoever K H; Gerlach L; Volm M; Lorenz W J
Response of the R3327-AT1 Dunning prostate tumor to fast neutrons and cobalt-60.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1989;165(4):283-5.
1989: Sonka J; Schossig U; Vogt-Schaden M; Volm M
Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.
Cancer chemotherapy and pharmacology 1989;24(1):33-40.
1989: Volm M; Efferth T; Bak M; Mattern J
Detection of drug resistance in human ovarian carcinoma.
Archives of gynecology and obstetrics 1989;244(2):123-8.
1989: Volm M; Bak M; Efferth T; Mattern J
Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface-membrane glycoprotein.
Journal of cancer research and clinical oncology 1989;115(1):17-24.
1988: Efferth T; Volm M
Rapid detection assays for multidrug resistance.
Arzneimittel-Forschung 1988;38(12):1771-4.
1988: Volm M; Bak M; Efferth T; Mattern J
Induced multidrug-resistance in murine sarcoma 180 cells grown in vitro and in vivo and associated changes in expression of multidrug-resistance DNA-sequences and membrane glycoproteins.
Anticancer research 1988;8(6):1169-78.
1988: Grancharov K C; Koch M; Volm M; Kolar G F
Synthesis and cytotoxic effects of hydroxymethyl-3-pyridyl- and 2-chloro-5-pyridyltriazene derivatives.
Cancer letters 1988;41(3):271-9.
1988: Volm M; Bak M; Mattern J
Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.
Arzneimittel-Forschung 1988;38(8):1189-93.
1988: Mattern J; Bak M; Hoever K H; Volm M
Development of drug resistance in a human epidermoid lung carcinoma xenograft line.
British journal of cancer 1988;58(1):30-3.
1988: Volm M; Bak M; Efferth T; Lathan B; Mattern J
Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4.
Anticancer research 1988;8(4):531-5.
1988: Volm M; Bak M; Hahn E W; Mattern J; Weber E
DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma.
Cytometry 1988;9(2):183-8.
1988: Volm M; Drings P; Hahn E W; Mattern J
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
British journal of cancer 1988;57(2):198-200.
1988: Volm M; Mattern J; Müller T; Drings P
Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study.
Anticancer research 1988;8(1):105-12.
1987: Volm M; Drings P; Kleine W; Mattern J
Flow cytometry as a tool for the prognostic assessment of patients with lung and ovarian carcinomas.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1987;163(12):791-4.
1987: Volm M; Mattern J
Clinical prognostic relevance of growth of human adenocarcinomas of the lung in nude mice.
Anticancer research 1987;7(6):1129-32.
1987: Mattern J; Bak M; Volm M
Occurrence of a multidrug-resistant phenotype in human lung xenografts.
British journal of cancer 1987;56(4):407-11.
1987: Bak M; Mattern J; Volm M
Maintenance of morphology and tumour marker production in human epidermoid lung carcinoma xenografts.
In vivo (Athens, Greece) 1987;1(5):319-26.
1987: Volm M; Efferth T; Günther A; Lathan B
Detection of murine S180 cells expressing a multidrug resistance phenotype using different in vitro test systems and a monoclonal antibody.
Arzneimittel-Forschung 1987;37(7):862-7.
1987: Volm M; Mattern J; Vogt-Schaden M; Wayss K
Flow cytometric analysis of primary lung carcinomas and their lymph node metastases.
Anticancer research 1987;7(1):71-6.
1987: Mattern J; Wayss K; Volm M
Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.
In vivo (Athens, Greece) 1987;1(1):23-6.
1986: Volm M; Drings P; Mattern J; Sonka J; Vogt-Moykopf I; Wayss K
Relevance of DNA-fluorimetry and short-term resistance testing for adjuvant treatment of non-small cell lung carcinomas.
Anticancer research 1986;6(5):931-4.
1985: Volm M; Drings P; Mattern J; Sonka J; Vogt-Moykopf I; Wayss K
Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma.
Cancer 1985;56(6):1396-403.
1985: Sonka J; Stöhr M; Vogt-Schaden M; Volm M
Anthracycline resistance and consequences of the in situ-in vitro transfer.
Cytometry 1985;6(5):437-44.
1985: Volm M; Mattern J; Sonka J; Vogt-Schaden M; Wayss K
DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior.
Cytometry 1985;6(4):348-56.
1985: Mattern J; Jäger S; Sonka J; Wayss K; Volm M
Growth of human bronchial carcinomas in nude mice.
British journal of cancer 1985;51(2):195-200.
1983: Sonka J; Stöhr M; Vogt-Schaden M; Volm M
Isopycnic density-gradient centrifugation: a separation parameter which improves flow cytometric measurements on heterogeneous tumors.
Cytometry 1983;4(2):141-9.

Sign-in to see more